Fig. 1: Expression and subcellular distribution of MIR22HG.
From: MIR22HG inhibits breast cancer progression by stabilizing LATS2 tumor suppressor
a MIR22HG expression in 36 pairs of cancerous and adjacent normal breast tissues detected by real-time PCR, with β-actin as internal control. b MIR22HG expression in normal breast epithelial cell line MCF10A and breast cancer cell lines MCF7, MDA-MB-231, BT549, and SKBR3 detected by real-time PCR, with β-actin as internal control. c MIR22HG expression in subcellular fractions of MDA-MB-231 cells detected by real-time PCR, with U6 and GAPDH as nuclear and cytoplasmic markers, respectively. d Fluorescence in situ hybridization analysis revealed that MIR22HG (red) was mainly located in the cytoplasm. DAPI-stained nuclei are in blue (in 63*oil lens). *P < 0.05, **P < 0.01. All experiments were repeated thrice.
